A 10-year follow-up of infliximab monotherapy for refractory uveitis in Behçet’s syndrome
Abstract Infliximab (IFX) was the first biologic introduced for refractory uveitis treatment in Behçet’s syndrome (BS). However, there have been few reports on the safety and efficacy of IFX monotherapy over follow-up periods of more than 10 years. This retrospective study evaluated the 10-year safe...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | article |
| Language: | EN |
| Published: |
Nature Portfolio
2020
|
| Subjects: | |
| Online Access: | https://doaj.org/article/c2c6986109f94e438d98391d829b7e87 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|